Shares of Travere Therapeutics, Inc. (TVTX) plummeted nearly 8% on Thursday, November 8th, after the biopharmaceutical company announced the pricing of a public offering of common stock that could dilute existing shareholders.
On Wednesday evening, November 7th, Travere Therapeutics revealed that it had priced an underwritten public offering of approximately 7.81 million shares of its common stock at $16 per share. The offering is expected to raise gross proceeds of $125 million for the company.
The news of the share issuance was met with a significant sell-off, as investors anticipated a dilutive impact on the company's outstanding shares. Travere Therapeutics' stock opened at $17.25 on November 8th but quickly shed nearly 8% of its value, closing the trading session at $15.88.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.